BDBM152931 US8993612, 5
SMILES: O=C(Cn1cnc2ccccc12)Nc1ccc(cc1)-n1nc(cc1C1CC1)C1CC1
InChI Key: InChIKey=MAJKGCYRUWETGW-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Calcium release-activated calcium channel (Homo sapiens (Human)) | BDBM152931 (US8993612, 5) | KEGG UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 383 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8993612 (2015) BindingDB Entry DOI: 10.7270/Q2CN72NK | |||||||||||
More data for this Ligand-Target Pair |